IR-MED’s AI-Powered Infra-Red Spectrographic Decision Support System PressureSafe Device Demonstrates High Efficacy in Detecting Pressure Injuries with 96% Accuracy: Potential to Set a New Standard of Care
Rosh Pina, Israel, July 17, 2023 (GLOBE NEWSWIRE) — IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven Infra-Red spectrographic analysis technology platform to address significant healthcare needs, announced today topline interim results from a clinical study of PressureSafe, a noninvasive handheld optical monitoring device that supports early detection of pressure injuries (PI) to the skin and underlying tissue.
Related news for (IRME)
- IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment
- IR-MED CEO Issues Letter to Shareholders: Expanding Our Platform and Presenting New Clinical Data from Israel and the U.S.
- IR-MED Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers
- IR-MED’s PressureSafe™ Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel’s Largest HMO
- IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries